Event‐free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa‐2b or hydroxyurea/best available therapy (PROUD‐PV/CONTINUATION‐PV)

Jean‐Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva‐Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Heinz Gisslinger, Unknown

Open source

DOI: 10.1002/hem3.70137
Published: 2025-05
Container: HemaSphere
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/hem3.70137,
  title = {Event‐free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa‐2b or hydroxyurea/best available therapy (PROUD‐PV/CONTINUATION‐PV)},
  author = {Jean‐Jacques Kiladjian and Christoph Klade and Pencho Georgiev and Dorota Krochmalczyk and Liana Gercheva‐Kyuchukova and Miklos Egyed and Petr Dulicek and Arpad Illes and Halyna Pylypenko and Lylia Sivcheva and Jiří Mayer and Vera Yablokova and Kurt Krejcy and Victoria Empson and Hans C. Hasselbalch and Robert Kralovics and Heinz Gisslinger and Unknown},
  year = {2025},
  journal = {HemaSphere},
  doi = {10.1002/hem3.70137},
  url = {https://doi.org/10.1002/hem3.70137}
}

RIS

TY  - JOUR
TI  - Event‐free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa‐2b or hydroxyurea/best available therapy (PROUD‐PV/CONTINUATION‐PV)
AU  - Jean‐Jacques Kiladjian
AU  - Christoph Klade
AU  - Pencho Georgiev
AU  - Dorota Krochmalczyk
AU  - Liana Gercheva‐Kyuchukova
AU  - Miklos Egyed
AU  - Petr Dulicek
AU  - Arpad Illes
AU  - Halyna Pylypenko
AU  - Lylia Sivcheva
AU  - Jiří Mayer
AU  - Vera Yablokova
AU  - Kurt Krejcy
AU  - Victoria Empson
AU  - Hans C. Hasselbalch
AU  - Robert Kralovics
AU  - Heinz Gisslinger
AU  - Unknown
PY  - 2025
JO  - HemaSphere
DO  - 10.1002/hem3.70137
UR  - https://doi.org/10.1002/hem3.70137
ER  -

APA

Kiladjian, J., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva‐Kyuchukova, L., Egyed, M., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Krejcy, K., Empson, V., Hasselbalch, H. C., Kralovics, R., Gisslinger, H., & Unknown (2025). Event‐free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa‐2b or hydroxyurea/best available therapy (PROUD‐PV/CONTINUATION‐PV). HemaSphere. https://doi.org/10.1002/hem3.70137

Source records

crossref · retrieved 2026-11-04T07:50:33.491Z